注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Galectin Therapeutics Inc是一家生物技術公司,專注於開發治療方法,以改善纖維性疾病、慢性肝病和癌症患者的生活。該公司的候選產品包括半乳糖凝集素-3抑製劑,這是一種Belapectin(GR-MD-02)和GM-CT-01。該公司的主導藥物Belagulatin是一種基於碳水化合物的藥物,可抑制Galectin-3蛋白,該蛋白直接參與多種炎症、纖維化和惡性疾病。該公司正在使用半乳糖凝集素-3抑製劑治療非酒精性脂肪性肝炎(NASH)患者的晚期肝纖維化和肝硬化。該公司還設計了一項IIb/III期臨床研究,即NAVIGATE試驗,評估其半乳糖凝集素-3抑製劑貝拉果膠(GR-MD-02)預防非酒精性脂肪性肝炎肝硬化患者食管靜脈曲張的安全性和有效性。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Kary Eldred | 50 | 2018 | Independent Director |
Kevin H. Mayo | - | - | Member of the Scientific Board |
Eric Lawitz | - | - | Member of Clinical Advisory Board |
Benjamin S. Carson | 73 | 2023 | Independent Director |
Marc Rubin | 69 | 2011 | Independent Director |
Gilbert F. Amelio | 81 | 2009 | Independent Director |
Kevin D. Freeman | 62 | 2011 | Independent Vice Chairman of the Board |
Anatole A. Klyosov | 77 | 2000 | Co-founder & Member of the Scientific Board |
Stephen A. Harrison | - | - | Member of Clinical Advisory Board |
Brent Tetri | - | - | Member of Clinical Advisory Board |
Richard E. Uihlein | 79 | 2017 | Independent Chairman |
Naga Chalasani | - | - | Member of Clinical Advisory Board |
Joel Lewis | 54 | 2017 | President, CEO & Director |
Thomas D. Schiano | - | - | Member of Clinical Advisory Board |
Ram Subramanian | - | - | Member of Clinical Advisory Board |
Arun J. Sanyal | - | - | Member of Clinical Advisory Board |
Elissa J. Schwartz | 53 | 2020 | Independent Director |
Richard A. Zordani | 51 | 2020 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核